论文部分内容阅读
目的探讨替吉奥联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法选取2013年1月至2013年8月间收治的NSCLC患者118例,根据随机数字表法分为观察组和对照组,每组59例。对照组患者予以吉西他滨联合顺铂(GP方案)治疗,观察组患者予以替吉奥联合顺铂治疗,两组均以4周为1个周期,直至病情进展或死亡或出现不能耐受的不良反应而终止治疗。比较两组患者治疗后的临床疗效,评价无进展生存时间(PFS)与总生存时间(OS),并比较两组患者的急性与亚急性毒性反应。结果观察组患者部分缓解(PR)、客观缓解率(ORR)、疾病控制率(DCR)均高于对照组,而疾病进展(PD)低于对照组,中位PFS、中位OS均长于对照组,不良反应发生率均低于对照组,差异均有统计学意义(P<0.05)。结论替吉奥联合顺铂为治疗晚期NSCLC的临床疗效较好,患者生存时间延长,且不良反应发生率低,对晚期NSCLC的临床治疗有一定的指导和借鉴意义。
Objective To investigate the clinical efficacy and safety of ticlopidine combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 118 patients with NSCLC who were admitted between January 2013 and August 2013 were divided into observation group and control group according to the random number table method, with 59 cases in each group. Patients in the control group were treated with gemcitabine combined with cisplatin (GP regimen), and patients in the observation group were treated with getigmine plus cisplatin. Both groups were treated with one cycle of 4 weeks until progression or death or unacceptable side effects And termination of treatment. The clinical efficacy of the two groups were compared after treatment, the progression-free survival time (PFS) and overall survival time (OS) were evaluated. The acute and subacute toxicities were compared between the two groups. Results The partial remission (PR), objective response rate (ORR) and disease control rate (DCR) in the observation group were significantly higher than those in the control group, while the disease progression (PD) was lower than that in the control group. The median PFS and median OS were longer than those in the control Group, the incidence of adverse reactions were lower than the control group, the difference was statistically significant (P <0.05). CONCLUSION: The combination of ticlopidine and cisplatin is effective in the treatment of advanced non-small cell lung cancer (NSCLC). The survival time of patients with NSCLC is prolonged and the incidence of adverse reactions is low. Therefore, it is helpful to the clinical treatment of advanced NSCLC.